Diphtheria toxin variant

Details Diphtheria toxin variant Diphtheria toxin variant

2009-02-09

2011-11-01

Borin, Michael (Department: 1631)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C424S832000, C424S236100, C424S238100

Reexamination Certificate

active

08048985

ABSTRACT:
The present invention relates to methods and compositions of modified variants of diphtheria toxin (DT) that reduce binding to vascular endothelium or vascular endothelial cells, and therefore, reduce the incidence of Vascular Leak Syndrome. One aspect of the present invention relates to a polypeptide toxophore from a modified DT, wherein the mutation is the substitution or deletion at least one amino acid residue at the amino acid residues 6-8, 28-30 or 289-291 of native DT. Another aspect of the present invention relates to a fusion protein which comprises a modified DT and a non-DT fragment. Another aspect of the present invention relates to the use of modified DT for the treatment of cancer.

REFERENCES:
patent: 4675382 (1987-06-01), Murphy
patent: 4830962 (1989-05-01), Gelfand et al.
patent: 5080898 (1992-01-01), Murphy
patent: 5208021 (1993-05-01), Johnson et al.
patent: 5352447 (1994-10-01), Johnson et al.
patent: 5510105 (1996-04-01), Strom
patent: 5607675 (1997-03-01), Strom
patent: 5614191 (1997-03-01), Puri et al.
patent: 5616482 (1997-04-01), Williams
patent: 5677148 (1997-10-01), Williams
patent: 5681810 (1997-10-01), Villemez et al.
patent: 5703039 (1997-12-01), Williams et al.
patent: 5763250 (1998-06-01), Williams et al.
patent: 5827934 (1998-10-01), Villemez et al.
patent: 5830478 (1998-11-01), Raso et al.
patent: 5843462 (1998-12-01), Conti-Fine
patent: 5843711 (1998-12-01), Collier et al.
patent: 5863891 (1999-01-01), Williams et al.
patent: 5932471 (1999-08-01), Williams et al.
patent: 6022950 (2000-02-01), Murphy
patent: 6099842 (2000-08-01), Pastan et al.
patent: 6566500 (2003-05-01), Vitetta et al.
patent: 2003/0017979 (2003-01-01), Mack et al.
patent: 2003/0124147 (2003-07-01), Vallera et al.
patent: 2003/0143193 (2003-07-01), Vitetta
patent: 2003/0176331 (2003-09-01), Rosenblum
patent: 2004/0009148 (2004-01-01), Vitetta et al.
patent: WO 00/58456 (2000-10-01), None
patent: WO 00/58456 (2000-10-01), None
Wells et al. Biochemistry 29(37): 8509-8517, 1990.
Ngo et al. (Mar. 2, 1995) “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 492-495.
Baluna et al., “Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome”,Proc. Natl. Acad. Sci. USA., 96(7):3957-3962 (1999).
Database Registry, RN 301412-09-9. Sequence No. 20224 from EP 1033405.
Foss et al., “Biological correlates of acute hypersensitivity events with DAB(398)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication”,Clinical Lymphoma, 1(4):298-302 (2001). Abstract.
Kaczorek et al., “Nucleotide Sequence and Expression of the Diphtheriatox228 Gene inEscherichia coli”, Science, vol. 221(4613), pp. 855-868, (1983).
Sequence Alignment from UniProt Database, Accession No. P005689, Jul. 21, 1986.

Affiliated with

Also associated with

Rating

Diphtheria toxin variant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diphtheria toxin variant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diphtheria toxin variant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4308804